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Abstract
t(11;14)-positive mantle cell lymphoma predominantly affects men, but the causes for this 
male predominance are still unknown. Here, we show  that cytogenetic loss of chromosome 
Y can be detected in up to 28% of t(11;14)-positive lymphoma. By FISH, chromosome Y loss 
is enriched in, or even restricted to, the t(11;14)-positive clone in 83% of the investigated 
mantle cell lymphoma. Moreover, DNA microarray and FISH analyses identified biallelic 
losses of Xp/Yp in 4 mantle cell lymphoma with a minimal region of deletion in the 
pseudoautosomal region 1. Our findings provide evidence for a pseudoautosomal region 1-
linked tumor suppressor gene locus that might be associated with male predominance in this 
lymphoma through age-related loss of the Y chromosome. 
Introduction
Mantle cell lymphoma (MCL) is a B-cell lymphoproliferative disorder which predominantly 
affects men. In a large retrospective survey of  the European MCL Network including 304 
patients, median age was 63 years at first diagnosis with a male preponderance of  76% [1]. 
The genetic hallmark of MCL is the translocation t(11;14)(q13;q32) which leads to 
overexpression of the CCND1 gene encoding Cyclin D1. Although recent studies revealed a 
number of  genomic alterations and differentially expressed genes in MCL, the causes for the 
male predominance are still unknown. Hormonal differences might contribute to this gender 
imbalance. Another hypothesis is that male predominance in MCL results from a sex 
chromosome-linked genetic or epigenetic alteration. Interestingly, some cytogenetic studies 
on MCL reported recurrent loss of the whole chromosome Y [2-4]. In the present report, we 
demonstrate the loss of chromosome Y loss to be a recurrent secondary aberration in MCL. 
Moreover, we identified biallelic losses in the pseudoautosomal region 1 (PAR1)-linked tumor 
suppressor gene, which might fit to the location of a tumor suppressor gene. 
Design and Methods
Calculating frequency of chromosome Y loss: For calculating frequency of chromosome Y 
loss in MCL, data from the Mitelman Database of  Chromosome Aberrations in Cancer 
[cgap.nci.nih.gov/Chromosomes/Mitelman, October 2007 edition] was analyzed. In total, 365 
entries from t(11;14)-positive B-cell Non-Hodgkin Lymphoma (B-NHL) in male patients 
(excluding plasmocytoma/multiple myeloma, "NHL not otherwise specified" and immature 
NHL) were found, using karyotype parsing software from the Progenetix project [5, 6]. In 
addition, frequency of  chromosome Y loss was calculated in 80 cases of  t(11;14)-positive 
lymphoma in male patients karyotyped at the Institute of Human Genetics, Kiel (University 
Hospital Schleswig-Holstein, Campus Kiel) between 1987 and 2007.
3MCL used for FISH: Cytogenetic suspensions from 21 MCL of male patients were selected 
from files of the Institute of Human Genetics (University Hospital Schleswig-Holstein, 
Campus Kiel). Median age was 64 (ranged from 37 to 75) and all cases showed loss of 
chromosome Y by cytogenetic analyses. 
Fluorescence in situ hybridization (FISH): Triple-color FISH was performed using the 
commercially available locus-specific identifier (LSI) IGH/CCND1 dual color, dual fusion 
translocation probe (Abbott/ Vysis, Downers Grove, IL, USA) in combination with a probe for 
chromosome region Yq12 (CEP Y Sat III, spectrum aqua, Abbott/ Vysis). For PAR1-FISH 
locus-specific probes were designed, which consisted of differentially labeled bacterial 
artificial chromosomes (BAC/PAC) clones, including RP11-800K15 (SHOX), RP4-674K6 
(CSF2RA), and RP11-475E20 (CRLF2). The KAL gene locus located in Xp22.31 was 
analyzed by FISH using the LSI Kallmann Region Probe (Abbott/Vysis). Probe preparation 
and FISH was performed using reported methods [7] on fixed nuclei derived from cytogenetic 
analyses.
100K GeneChip analysis: Recently obtained 100K GeneChip data (GeneChip Human 
Mapping 100K Set, Affymetrix, Santa Clara, CA, USA) (Nieländer et al., in preparation) of  20 
primary MCL from male patients was evaluated with regard to aberrations targeting the 
pseudoautosomal regions of the sex chromosomes. Among those were five cases of the 
above described FISH panelcases 4, 6, 9, 14 and 18). Probe preparation and array 
hybridization was performed according to the GeneChip Human Mapping 100K assay 
protocol (Affymetrix, Santa Clara, CA) (http://www.affymetrix.com). Copy number analysis 
was performed using the CNAG program v2.0 [8]. As euploid reference arrays 90 Hapmap 
samples provided by Affymetrix (30 CEPH trios) were used (http://www.affymetrix.com/
support/technical/sample_data/hapmap_trio_data.affx). Segmentation of raw  copy number 
data was performed using the Hidden Markov Model approach provided by CNAG. Here, 
data was evaluated with regard to aberrations targeting the pseudoautosomal regions of  the 
sex chromosomes.
Results and Discussion
Using the Progenetix software tools on data from the Mitelmann database, we here show 
that 42 of 365 (11.5%) cytogenetically analyzed t(11;14)-positive lymphoma in male patients 
harbor a deletion of  the Y chomosome. Similarly, 22 of  80 (27.5%) t(11;14)-positive 
lymphoma in male patients cytogenetically analyzed in our own institution showed loss of the 
Y chromosome. These findings indicate that the loss of  the Y chromosome is a recurrent 
cytogenetic event in MCL. 
Loss of the Y chromosome is known to be a common aging phenomenon in cells of elderly 
males [9], but recent studies also suggest significance in tumor development, particularly in 
prostate cancer [10-12]. To differentiate between age-related random and clonal losses of the 
Y chromosome, we aimed at analyzing whether loss of chromosome Y is restricted to the 
4t(11;14)-positive MCL tumor cells or whether this change occurs also in the normal cells of 
the biopsies, e.g. due to an age-related effect. Therefore, we performed triple-color FISH in 
21 MCL of male patients harboring a chromosome Y loss to detect IGH-CCND1 fusion and 
chromosome Y loss simultaneously (Figure 1A,B). The cytogenetically described loss of the 
Y chromosome was confirmed by FISH in all but 3 of  the 21 MCL cases. Compatibly, 
cytogenetic studies of these 3 MCL cases showed marker chromosomes, which presumably 
harbor the Yq12 chromosome material detected by the FISH probe. FISH analyses 
demonstrated that in 12 of  the remaining 18 MCL, loss of  chromosome Y was present in the 
clone with the translocation t(11;14) whereas a maximum of 3% (Median 1.1%, range 0-3%) 
of the t(11;14)-negative cells showed Y chromosomal loss (Figure 1A). In additional 3 MCL 
cases, 9% (case 15), 12% (case 5) and 16% (case 13) of the t(11;14)-negative cells harbor a 
chromosome Y deletion, but loss of chromosome Y was obviously more frequent (5.9–8.3 
fold) in the  t(11;14)-positive cells. Accordingly, loss of chromosome Y seems to be a clonal 
feature of the t(11;14)-positive tumor cells in 83% of the investigated MCL. In 5 of  the 15 
MCL cases with clonal chromosome Y loss we additionally identified at least 3% t(11;14)-
positive cells without chromosome Y deletion (cases 11-15). The presence of the Y 
chromosome in these lymphoma cells indicates that loss of chromosome Y occurred 
secondary to t(11;14).
It is widely assumed that the Y chromosome predominantly lacks genes involved in 
oncogenesis. Most of the few  genes of chromosome Y are localized at the pseudoautosomal 
regions which show  homology and recombine with two segments on the X chromosome. A 
recent arrayCGH study identified complete loss of the terminal short arm of the X 
chromosome including the Kallmann (KAL) gene locus in Xp22.31 and the PAR1 in one 
t(11;14)-positive primary MCL [13]. Here, we evaluated recently obtained 100K GeneChip 
data of  20 primary MCL from male patients with regard to aberrations targeting the 
pseudoautosomal regions of the sex chromosomes (Nieländer et al., in preparation). There 
are no tags for chromosome Y on the microarray except for the PARs. Remarkably, in 2 of 
the MCL cases with chromosome Y deletion GeneChip analysis identified a region of 
complete loss in the PAR1 in Xp/Yp (Figure 1C). According to the GeneChip data, the 
minimally deleted region spanned approximately 2.5 Mb from the Xp-telomere to the SNP 
“rs5982788“, including 16 pseudoautosomal genes (NCBI Build 35) (Figure 1, Table 1). FISH 
analyses confirmed homozygous loss of the SHOX, CSF2RA, and CRLF2 genes in both 
MCL showing biallelic loss of  the PAR1 in the GeneChip data. Moreover, a FISH screening of 
the remaining 16 MCL with chromosome Y loss detected one additional case showing 
biallelic loss of  all these gene loci. The case described by Rubio-Moscardo et al., 2005 [13] 
was also confirmed by FISH to harbor biallelic loss of  the PAR1. To further confirm the border 
of the homozygously deleted region, we performed FISH analyses for the KAL locus in the 
three MCL with Xp-deletion detected here. In 2 of  these cases, homozygous loss did not 
comprise the KAL gene locus. The amount of cells showing biallelic loss of the PAR1 in the 
samples studied herein corresponded approximately to the tumor cell content which was 
5calculated by t(11;14)-FISH (Figure 1D). The signal constellation in the putative non-
tumorous cells indicated that both X-chromosomal and Y-chromosomal PAR1 were present, 
ruling out a constitutional copy number polymorphism (Figure 1E). These findings suggest 
deletion of the X-chromosomal PAR1 to be restricted to the t(11;14)-positive cells in these 
MCL. 
In summary, the clonality of chromosome Y loss in t(11;14)-positive tumor cells provides 
evidence for its relevance as secondary aberration in MCL. It seems that its role in MCL 
development might be underestimated so far. Our data may also rule out the hypothesis that 
male predominance is caused by loss of  chromosome Y in normal lymphoid cells, 
predisposing them to the development of  MCL. The detection of a deletion in Xp22.33 in 
addition to chromosome Y loss suggests the involvement of a pseudoautosomal tumor 
suppressor gene. Inactivation of  a PAR-linked candidate tumor suppressor gene in 
combination with Y chromosome loss through an age-related effect in elderly cells could be a 
plausible explanation for the male predominance observed in MCL. Remarkably, 
pseudoautosomal linkage has been also proposed for Hodgkin lymphoma [14, 15]. It may be 
of particular interest, that a cluster of cytokine-receptor genes resides on the PAR1 region 
[16]. Aberrant expression of chemokines and chemokine receptors has been reported to play 
a role in malignant heamatopoietic cells [17, 18]. Future studies, including mutation and 
expression analyses of  genes located in PAR1, might lead to the identification of  candidate 
genes involved in MCL lymphomagenesis.
Authors’ contributions
IN: conception and design, research performance, data analysis and interpretation, 
manuscript writing; JIM: data analysis and interpretation; FW: microarray analysis; MB: data 
analysis and interpretation; SG: data analysis and interpretation; LH: material  collection, 
cytogenetic analysis; DH: microarray data analysis; WK: material collection, pathology 
review; MK: microarray data analysis; CP: material collection; JAM: data analysis and 
interpretation; MD: data analysis and interpretation; NA: data analysis and interpretation; RS: 
conception and design, data interpretation, manuscript writing. All authors took part in the 
revision of the manuscript and approved the final version.
Conflicts of interest
The authors reported no potential conflicts of interest.
6References
1. Tiemann, M., et al., Histopathology, cell proliferation indices and clinical outcome in 304 patients with 
mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J 
Haematol, 2005. 131(1): p. 29-38.
2. Espinet, B., et al., Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 
13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet, 1999. 111(1): p. 92-8.
3. Bigoni, R., et al., Secondary chromosome changes in mantle cell lymphoma: cytogenetic and 
fluorescence in situ hybridization studies. Leuk Lymphoma, 2001. 40(5-6): p. 581-90.
4. Au, W.Y.,  et al., Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymphoma, 
2002. 43(4): p. 783-91.
5. Progenetix - cytogenetic abnormalities in human cancer. www.progenetix.net.
6. Baudis, M., Online database and bioinformatics toolbox to support data mining in cancer cytogenetics. 
Biotechniques, 2006. 40(3): p. 269-70, 272.
7. Martin-Subero, J.I., et al.,  Interphase FISH assays for the detection of translocations with breakpoints 
in immunoglobulin light chain loci. Int J Cancer, 2002. 98(3): p. 470-4.
8. Nannya, Y., et al., A robust algorithm for copy number detection using high-density oligonucleotide 
single nucleotide polymorphism genotyping arrays. Cancer Res, 2005. 65(14): p. 6071-9.
9. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer 
Cytogenetics Group (UKCCG). Genes Chromosomes Cancer, 1992. 5(1): p. 83-8.
10. Vijayakumar, S., et al.,  The human Y chromosome suppresses the tumorigenicity of PC-3, a human 
prostate cancer cell line, in athymic nude mice. Genes Chromosomes Cancer, 2005. 44(4): p. 365-72.
11. Vijayakumar, S., et al., Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster 
in prostate cancer using array-based comparative genomic hybridization. Cancer Res, 2006.  66(8): p. 
4055-64.
12. Pyakurel,  P., et al., CGH of microdissected Kaposi's sarcoma lesions reveals recurrent loss of 
chromosome Y in early and additional chromosomal changes in late tumour stages.  AIDS, 2006. 
20(14): p. 1805-12.
13. Rubio-Moscardo, F., et al.,  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays 
define a leukemic subgroup of disease and predict patient outcome. Blood, 2005. 105(11): p. 4445-54.
14. Horwitz, M. and P.H. Wiernik, Pseudoautosomal linkage of Hodgkin disease. Am J Hum Genet,  1999. 
65(5): p. 1413-22.
15. Horwitz, M.S. and M.E. Mealiffe, Further evidence for a pseudoautosomal gene for Hodgkin's 
lymphoma: Reply to 'The familial risk of Hodgkin's lymphoma ranks among the highest in the Swedish 
Family-Cancer Database' by Altieri A and Hemminki K. Leukemia, 2007. 21(2): p. 351.
16. Kremer, E.,  et al., A cytokine receptor gene cluster in the X-Y pseudoautosomal region? Blood, 1993. 
82(1): p. 22-8.
17. Trentin, L.,  et al., Homeostatic chemokines drive migration of malignant B cells in patients with non-
Hodgkin lymphomas. Blood, 2004. 104(2): p. 502-8.
18. Durig, J.,  U. Schmucker, and U. Duhrsen,  Differential expression of chemokine receptors in B cell 
malignancies. Leukemia, 2001. 15(5): p. 752-6.
7Figure legend
Figure 1:
A) Percentages of cells with chromosome Y loss in both the t(11;14)(q13;q32)-positive MCL 
tumor cells (left column) and the t(11;14)(q13;q32)-negative normal cells (right column) of  18 
analyzed primary MCL with chromosome Y loss by FISH. In each case, 100  tumor cells and 
100 normal cells were evaluated by FISH. MCL showing loss in Xp22.33 are marked by a red 
box. 
B) FISH on interphases of  MCL 9 using the LSI IGH/CCND1 dual color probe labeled in red/
green in combination with a probe for Yq12 labeled in blue. Colocalization of red and green 
signals indicates a MCL nucleus (red arrow) harboring a translocation t(11;14)(q13;q32). A 
blue signal indicating the presence of chromosome Y was only detectable in the nuclei of 
t(11;14)-negative cells (yellow arrow). 
C) GeneChip copy number data of MCL 6 showing a homozygous deletion in the 
pseudoautosomal region 1 (PAR1) in Xp22.33. Black dots represent copy number estimators 
of the SNP probes smoothed by a median filter of  size n=3. The red line marks the result of 
the segmentation process. The profile of  genomic imbalances is shown from Xp telomere 
(left) to 8Mb (right) with a value of 1 indicating the presence of one X chromosome. The 
tumor cell content of this MCL was 85%.
D) Percentages of cells with biallelic PAR1 loss (green) compared to percentages of  t(11;14)-
positive cells (red) in the 3 MCL showing homozygous PAR1 deletion. Percentages for both 
alterations were determined in separate hybridization experiments evaluating 100 cells each. 
E) FISH on interphases of  MCL 7 using a locus-specific probe for the PAR1 region. The PAC 
clone RP4-674K6 targeting the CSF2RA locus in Xp22.33 was labeled in spectrum green 
and two pooled BAC clones RP13-156P1 and RP11-296N8 targeting a control locus in Xq28 
were labeled in spectrum orange. In cells with PAR1 deletion, no green signal was detectable 
(red arrow). The cell marked by a yellow  arrow  showed two green signals indicating the 
presence of  both X-chromosomal and Y-chromosomal PAR1. False color display using the 
ISIS software version 5.1.9 (Metasystems, Altlussheim, Germany). 
